Compare KYN & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KYN | TMDX |
|---|---|---|
| Founded | 2004 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.5B |
| IPO Year | N/A | 2019 |
| Metric | KYN | TMDX |
|---|---|---|
| Price | $13.57 | $77.38 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $148.22 |
| AVG Volume (30 Days) | 415.2K | ★ 1.1M |
| Earning Date | 01-01-0001 | 05-05-2026 |
| Dividend Yield | ★ 8.99% | N/A |
| EPS Growth | N/A | ★ 382.18 |
| EPS | ★ 0.71 | 0.20 |
| Revenue | N/A | ★ $605,494,000.00 |
| Revenue This Year | N/A | $24.25 |
| Revenue Next Year | N/A | $18.75 |
| P/E Ratio | ★ $19.30 | $369.15 |
| Revenue Growth | N/A | ★ 37.13 |
| 52 Week Low | $11.31 | $60.11 |
| 52 Week High | $14.70 | $156.00 |
| Indicator | KYN | TMDX |
|---|---|---|
| Relative Strength Index (RSI) | 44.55 | 53.04 |
| Support Level | $12.93 | $64.90 |
| Resistance Level | $14.35 | $120.60 |
| Average True Range (ATR) | 0.26 | 4.00 |
| MACD | -0.04 | 1.38 |
| Stochastic Oscillator | 39.07 | 70.20 |
Kayne Anderson Energy Infrastructure Fund, Inc is a non-diversified, closed-end fund. Its investment objective is to provide a high after-tax total return with an emphasis on making cash distributions to the stockholder. The Company invests in various sectors, which include midstream energy companies, renewable infrastructure companies, and utility companies. The company seeks to achieve its objectives by investing a majority of its total assets in the securities of Energy Infrastructure companies.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.